#6Metabolic & Frontier
Eloralintide
selective amylin-receptor agonist
Evidence: human RCTReviewed 2026-07-25
Investigated uses
- Obesity and weight management in early clinical development.
Mechanism and hypotheses
- Eloralintide is a selective amylin-receptor agonist in clinical development for obesity.
- Hypothesized: Durability, comparative benefit and long-term safety remain investigational.
Human evidence
- Early randomized clinical development demonstrated dose-related weight reduction and expected gastrointestinal tolerability signals. Limitations: Early-phase sample sizes and follow-up do not establish long-term benefit–risk.
- A randomized, double-blind, placebo-controlled Phase 2 study evaluated eloralintide in 263 adults with obesity or overweight; later-stage ENLIGHTEN trials are underway.
- Sponsor reporting and an individual trial do not establish an approved product or complete long-term benefit-risk profile.
Safety highlights
- Nausea and other gastrointestinal events were prominent in early clinical studies.
- Long-term and rare-event safety is unknown.
Regulatory context
No FDA-approved product matching the exact catalog presentation was identified in this review.
Sources used for this entry
- PubMed search: Eloralintide — PubMed
- Drugs@FDA database — U.S. Food and Drug Administration
- EMA medicines search — European Medicines Agency
- NCT05295940: Eloralintide first-in-human study — ClinicalTrials.gov
- Eloralintide selective amylin-receptor agonist trial — The Lancet / PubMed
- Phase 2 eloralintide results in adults with obesity or overweight — Eli Lilly and Company